Showing 1 - 20 results of 38 for search '"прогестероновые рецепторы"', query time: 0.62s Refine Results
  1. 1
  2. 2
    Academic Journal

    Source: Reproductive health of woman; No. 1 (2021); 54-60 ; Reproductive health of woman; № 1 (2021); 54-60 ; Репродуктивне здоров'я жінки; № 1 (2021); 54-60 ; 2708-8731 ; 2708-8723

    File Description: application/pdf

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
    Academic Journal

    Source: Obstetrics, Gynecology and Reproduction; Vol 13, No 2 (2019); 85-94 ; Акушерство, Гинекология и Репродукция; Vol 13, No 2 (2019); 85-94 ; 2500-3194 ; 2313-7347

    File Description: application/pdf

    Relation: https://www.gynecology.su/jour/article/view/558/744; Karizbodagh M.P., Rashidi B., Sahebkar A. et al. Implantation window and angiogenesis. J Cell Biochem. 2017;118(12):4141–51. DOI:10.1002/jcb.26088.; Recurrent pregnancy loss. ESHRE Early Pregnancy Guideline Development Group. European Society of Human Reproduction and Embryology, 2017. 153 р. Available at: https://www.klinikum.uniheidelberg.de/fileadmin/frauenklinik/Gyn_Endokrinologie/images/PDF/ ESHRE_RPL_Guideline_28112017_FINAL.pdf.; Шарапова Е.И., Машина М.А., Кузьмин В.Н. Возможные пути оптимизации специализированной помощи бесплодной паре. Кремлевская медицина. Клинический вестник. 2014;(4):25–8.; Katzorke N., Vilella F., Ruiz M. et al. Diagnosis of endometrial-factor infertility: current approaches and new avenues for research. Geburtshilfe Frauenheilkd. 2016;76(6):699–703.; Dorostghoal M., Ghaffari H.O., Moramezi F, Keikhah N. Overexpression of endometrial estrogen receptor-alpha in the window of implantation in women with unexplained infertility. Int J Fertil Steril. 2018;12(1):37–42. DOI:10.22074/ijfs.2018.5118.; Толибова Г.Х. Эндометриальная дисфункция у женщин с бесплодием: патогенетические детерминанты и клинико-морфологическая диагностика: Автореф. дис. докт. мед. наук. СПб., 2018. 39 с.; Аганезов С.С., Эллиниди В.Н., Пономаренко К.Ю. и др. Особенности гормон-рецепторного взаимодействия в эндометрии при овуляторном менструальном цикле у женщин с нарушениями менструальной функции. Вестник Российской Военно-медицинской академии. 2018;(2):63–7.; Шуршалина А.В., Демура Т.А. Морфофункциональные перестройки эндометрия в «окно имплантации». Акушерство и гинекология. 2011;7(2):9–13.; Huang C., Sun H., Wang Z. et al. Increased Kruppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure. Cell Death Discov. 2018;6:4–23. DOI:10.1038/s41420-018-0088-8.; Крылова Ю.С., Кветной И.М., Айламазян Э.К. Рецептивность эндометрия: молекулярные механизмы регуляции имплантации. Журнал акушерства и женских болезней. 2013;62(2):63–74.; Qian Z.D., Weng Y., Wang C.F., Huang L.L. Research on the expression of integrin β3 and leukemia inhibitory factor in the decidua of women with cesarean scar pregnancy. BMC Pregnancy Childbirth. 2017;17(1):84. DOI:10.1186/s12884-017-1270-3.; Franasiak J.M., Holoch K.J., Yuan L. et al. Prospective assessment of midsecretory endometrial leukemia inhibitor factor expression versus ανβ3 testing in women with unexplained infertility. Fertil Steril. 2014;101(6):1724–31. DOI:10.1016/j.fertnstert.2014.02.027.; Wu F., Chen X., Liu Y. et al. Decreased MUC1 in endometrium is an independent receptivity marker in recurrent implantation failure during implantation window. Reprod Biol Endocrinol. 2018;16(1):60. DOI:10.1186/s12958-018-0379-1.; Wetendorf M., Wu S.P., Wang X. et al. Decreased epithelial progesterone receptor A at the window of receptivity is required for preparation of the endometrium for embryo attachment. Biol Reprod. 2017;96(2):313–26. DOI:10.1095/biolreprod.116.144410.; https://www.gynecology.su/jour/article/view/558

  8. 8
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 7 (2019); 13-20 ; Медицинский Совет; № 7 (2019); 13-20 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-7

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/2914/2845; Gao X., Yu L., Moore A.B., et al. Cadmium and proliferation in human uterine leiomyoma cells: evidence of a role for EGFR/MAPK pathways but not classical estrogen receptor pathways. Environ Health Perspect. 2015;123:331-336.; Islam M.S., Protic O., Giannubilo S.R., et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013;98:921-934.; Plewka D., Marczynski J., Morek M. et al. Receptors of hypothalamic-pituitary-ovarian-axis hormone in uterine myomas. Biomed Res Int. 2014;2014:521313.; Wakabayashi А., Takeda T., Tsuiji K., et al. Antiproliferative effect of adiponectin on rat uterine leiomyoma ELT-3 cells. Gynecol Endocrinol. 2011;27:33-38.; Islam M.S., Catherino W.H., Protic O., et al. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J Clin Endocrinol Metab. 2014;99:E775-E785.; Moravek M.B., Yin P., Ono M., et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21:1-12.; Reis F.M., Bloise E., Ortiga-Carvalho T.M. Hormones and pathogenesis of uterine fibroids. Best Practice & Research Clinical Obstetrics and Gynaecology. 2015;1-12.; O’Connor K.A., Ferrell R., Brindle E., et al. Progesterone and ovulation across stages of the transition to menopause. Menopause. 2009;16:1178-1187.; Bulun S.E., Moravek M.B., Yin P. et al. Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med. 2015;33:357-365.; Grings A.O., Lora V., Ferreira G.D., et al. Protein expression of estrogen receptors alpha and beta and aromatase in myometrium and uterine leiomyoma. Gynecol Obstet Invest. 2012;73:113-117.; Tsigkou A., Reis F.M., Lee M.H., et al. Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms. Fertil Steril. 2015;104:170-175.e171.; Ciavattini A., Di Giuseppe J., Stortoni P., et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet Gynecol Int. 2013;2013:173-184.; Luo N., Guan Q., Zheng L., et al. Estrogenmediated activation of fibroblasts and its effects on the fibroid cell proliferation. Transl Res. 2014;163:232-241.; Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012;358:223-231.; Осиновская Н.С., Иващенко Т.Э., Долинский А.К., Султанов И.Ю., Гимбовская С., ХоффманЭ., Беженарь В.Ф., Баранов В.С. Мутации гена MED12 у женщин с миомой матки. Генетика. 2013;49(12):1426-1431. [Osinovskaya N.S., Ivashchenko T.E., Dolinsky A.K., Sultanov I.Yu., Gimbovskaya S., Hoffman E., Bezhenar V.F., Baranov V.S. MED12 gene mutations in women with uterine myoma. Genetika. 2013;49(12):1426-1431] (In Russ).; Liu S., Yin P., Kujawa S.A., Coon J.S. V, Okeigwe I., Bulun S.E. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma. Oncogene. 2018 Dec 11. doi:10.1038/s41388-018-0612-6.; Адамян Л.В., Сонова М.М., Шамугия Н.М. Опыт применения селективных модуляторов рецеп- торов прогестерона в лечении миомы матки (обзор литературы). Проблемы репродукции. 2014;(4): 34-38 [Adamyan L.V., Sonova M.M., Shamugia N.M. Experience of using selective progesterone receptor modulators in the treatment of uterine fibroids (literature review). Problemy Reproduktsii. 2014;(4):34-38] (In Russ).; Шамугия Н.М., Адамян Л.В., Сонова М.М. и др. Новое в лечении миомы матки. Российский вестник акушера-гинеколога. 2015;3:76-80. [Shamugia N.M., Adamyan L.V., Sonova M.M, et al. New achievements in the treatment of uterine fibroids. Rossiyskiy Vestnik Akushera-Ginekologa. 2015;3:76-80.] (In Russ).; Адамян Л.В., Зайратьянц О.В., Тихомиров А.Л. и др. Антипролиферативное и проапоптоти- ческое действие селективного модулятора рецепторов прогестерона улипристала на лейомиому матки in vivo. Пробл. репродукции. 2014;3:25-28. [Adamyan L.V., Zaratyants O.V., Tikhomirov A.L., et al. The antiproliferative and proapoptotic effect of the selective progesterone receptor modulator ulipristal on uterine leiomyoma in vivo. Probl. Reproduktsii. 2014;3:25-28.] (In Russ).; Тихомиров А.Л., Казенашев В.В. Улипристал ацетат – новые возможности в лечении лей- омиомы матки. Акуш. и гин. 2013;9:97-100. [Tikhomirov A.L., Kazenashev V.V. Ulipristal acetate: new opportunities in the treatment of uterine leiomyoma. Akush i Gin. 2013;9:97-100.] (In Russ).; Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лече- ния. Монография. М., 2013. [Tikhomirov A.L. Myoma, pathogenetic rationale for organ preservation treatment. Monograph. M., 2013.] (In Russ).; Malik M., Britten J., Cox J., et al. Gonadotropinreleasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. Fertil Steril. 2015. 10.1016/j. fertnstert.2015.09.006 [Published online Sep 26, 2015.].; Chung Y.J., Chae B., Kwak S.H., et al. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Int J Med Sci. 2014;11:276-281.; Карева Е.Н. Мифепристон и миома матки. Фарматека. 2010;14:18-30. [Kareva E.N. Mifepristone and uterine fibroids. Pharmateca. 2010;14:18-30.] (In Russ).; Chabbert-Buffet N., Esber N., Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102:630-639.; Römer T. Long-term intermittent treatment with ulipristal acetate avoids hysterectomy (Langzeitintervalltherapie mit Ulipristalacetat vermeidet Hysterektomie). Der Privatarzt Gynäkologie. 2016;7(22-23). doi:10.1007/s41975-017-0002-4.; Ono M., Qiang W., Serna V.A., et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7:e36935.; Morikawa А., Ohara N., Xu Q., et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod. 2008;23:944-951.; Fischl F. Ulipristal acetate (UPA) as conservative fibroid treatment and bleeding control in uterus myomatosis (Ulipristalacetat (UPA) zur konservativen Myomtherapie und Blutungskontrolle bei Uterus myomatosus) Journal für Gynäkologische Endokrinologie. 2016;10(1):30–36.; Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Esmyahttp://www.richter.hu/en-S/investors/announcements/Pages/extraord171204b.aspx.; http://www.roszdravnadzor.ru/i/upload/images/2018/4/11/1523459448.3577-1-21581.pdf.; Donnez J., Courtoy G.E. & Dolmans M.-M. Fibroid management in premenopausal women. Climacteric. doi:10.1080/13697137.2018.1549216.; Donnez J., Courtoy G.E., Donnez O., Dolmans M.M. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online. 2018;37:216–23.; Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110:593–5.; Donnez J., Tatarchuk T.T., Bouchard P. et al. for the PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012;366:409-420.; Donnez J., Tomaszewski J., Vazquez F. et al. for the PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012;366:421-432.; Donnez J., Tomaszewski J., Vazquez F. et al., for the PEARL III Study Group. Long term treatment. Gynecology and Menopause. 2014:9-18.; Donnez J., Hudecek R., Donnez O. et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519-527.e513.; Donnez J., et al. PEARL IV PART 2. Fertil Steril. 2016;105(1):165-173.; Fauser B.C.J.M., Donnez J., Bouchard Ph., Barlow D.H., Vázquez F., Arriagada P., Skouby S.O., Palacios S., Tomaszewski Ja., Lemieszczuk B., William A.R.W. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017 Mar 7;12(3):e0173523. doi:10.1371/journal.pone.0173523.

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20